Literature DB >> 29962366

Effectiveness of an Assertive Community Treatment program for people with severe schizophrenia in mainland China - a 12-month randomized controlled trial.

Xingwei Luo1, Samuel F Law2, Xiang Wang1, Jingzheng Shi3, Wu Zeng4, Xiaoqian Ma1, Wendy Chow2, Shiyan Liu1, Wei Zhao1, Xiaoli Liu3, Shuqiao Yao1, Michael R Phillips5.   

Abstract

BACKGROUND: Assertive Community Treatment (ACT) is an evidence-based treatment program for people with severe mental illness developed in high-income countries. We report the first randomized controlled trial of ACT in mainland China.
METHODS: Sixty outpatients with schizophrenia with severe functional impairments or frequent hospitalizations were randomly assigned to ACT (n = 30) or standard community treatment (n = 30). The severity of symptoms and level of social functioning were assessed at baseline and every 3 months during the 1-year study. The primary outcome was the duration of hospital readmission. Secondary outcomes included a pre-post change in symptom severity, the rates of symptom relapse and gainful employment, social and occupational functioning, and quality of life of family caregivers.
RESULTS: Based on a modified intention-to-treat analysis, the outcomes for ACT were significantly better than those of standard community treatment. ACT patients were less likely to be readmitted [3.3% (1/30) v. 25.0% (7/28), Fisher's exact test p = 0.023], had a shorter mean readmission time [2.4 (13.3) v. 30.7 (66.9) days], were less likely to relapse [6.7% (2/30) v. 28.6% (8/28), Fisher's exact test p = 0.038], and had shorter mean time in relapse [3.5 (14.6) v. 34.4 (70.6) days]. The ACT group also had significantly longer times re-employed and greater symptomatic improvement and their caregivers experienced a greater improvement in their quality of life.
CONCLUSION: Our results show that culturally adapted ACT is both feasible and effective for individuals with severe schizophrenia in urban China. Replication studies with larger samples and longer duration of follow up are warranted.

Entities:  

Keywords:  Assertive Community Treatment (ACT); community mental health services; family psychoeducation; randomized controlled trial (RCT); schizophrenia

Mesh:

Year:  2018        PMID: 29962366     DOI: 10.1017/S0033291718001629

Source DB:  PubMed          Journal:  Psychol Med        ISSN: 0033-2917            Impact factor:   7.723


  5 in total

1.  A sequence analysis of hospitalization patterns and service utilization in patients with major psychiatric disorders in China.

Authors:  Xueyan Han; Feng Jiang; Jack Needleman; Moning Guo; Yin Chen; Huixuan Zhou; Yuanli Liu; Chen Yao; Yilang Tang
Journal:  BMC Psychiatry       Date:  2021-05-11       Impact factor: 3.630

Review 2.  Fit for Work and Life-an eight-week program for improvement of functionality and quality of life : A two-stage study.

Authors:  Kunigunde Pausch; Katrin Blanke; Verena Niederberger; Sarah Egli; Michael Rufer; Vladeta Ajdacic-Gross; Sebastian Olbrich; Mario Müller
Journal:  Neuropsychiatr       Date:  2022-04-15

3.  Community-based rehabilitation intervention for people with schizophrenia in Ethiopia (RISE): results of a 12-month cluster-randomised controlled trial.

Authors:  Laura Asher; Rahel Birhane; Helen A Weiss; Girmay Medhin; Medhin Selamu; Vikram Patel; Mary De Silva; Charlotte Hanlon; Abebaw Fekadu
Journal:  Lancet Glob Health       Date:  2022-04       Impact factor: 38.927

4.  Investigating the critical elements and psychosocial outcomes of Youth Flexible Assertive Community Treatment: a study protocol for an observational prospective cohort study.

Authors:  Marieke Broersen; Daan H M Creemers; Nynke Frieswijk; Ad A Vermulst; Hans Kroon
Journal:  BMJ Open       Date:  2020-04-06       Impact factor: 2.692

5.  Correlation Analysis of the Quality of Family Functioning and Subjective Quality of Life in Rehabilitation Patients Living with Schizophrenia in the Community.

Authors:  Ling Wang; Xi-Wang Fan; Xu-Dong Zhao; Bing-Gen Zhu; Hong-Yun Qin
Journal:  Int J Environ Res Public Health       Date:  2020-04-05       Impact factor: 3.390

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.